Obstructive lung disease: Difference between revisions
Line 86: | Line 86: | ||
! rowspan="4" style="background:#4479BA; color: #FFFFFF;" align="center" |Diseases | ! rowspan="4" style="background:#4479BA; color: #FFFFFF;" align="center" |Diseases | ||
! colspan="10" rowspan="1" style="background:#4479BA; color: #FFFFFF;" align="center" |Clinical manifestations | ! colspan="10" rowspan="1" style="background:#4479BA; color: #FFFFFF;" align="center" |Clinical manifestations | ||
! colspan=" | ! colspan="11" rowspan="1" style="background:#4479BA; color: #FFFFFF;" align="center" |Diagnosis | ||
|- | |- | ||
! colspan="5" rowspan="1" style="background:#4479BA; color: #FFFFFF;" align="center" |Symptoms | ! colspan="5" rowspan="1" style="background:#4479BA; color: #FFFFFF;" align="center" |Symptoms | ||
! colspan="5" rowspan="1" style="background:#4479BA; color: #FFFFFF;" align="center" |Signs | ! colspan="5" rowspan="1" style="background:#4479BA; color: #FFFFFF;" align="center" |Signs | ||
! rowspan="3" style="background:#4479BA; color: #FFFFFF;" align="center" |Lab findings | ! rowspan="3" style="background:#4479BA; color: #FFFFFF;" align="center" |Lab findings | ||
! colspan=" | ! colspan="5" style="background:#4479BA; color: #FFFFFF;" align="center" |PFT | ||
! colspan="3" rowspan="2" style="background:#4479BA; color: #FFFFFF;" align="center" |Imaging | ! colspan="3" rowspan="2" style="background:#4479BA; color: #FFFFFF;" align="center" |Imaging | ||
! rowspan="3" style="background:#4479BA; color: #FFFFFF;" align="center" |Gold standard | ! rowspan="3" style="background:#4479BA; color: #FFFFFF;" align="center" |Gold standard | ||
Line 110: | Line 110: | ||
! rowspan="2" style="background:#4479BA; color: #FFFFFF;" align="center" |TLC | ! rowspan="2" style="background:#4479BA; color: #FFFFFF;" align="center" |TLC | ||
! rowspan="2" style="background:#4479BA; color: #FFFFFF;" align="center" |DLCO | ! rowspan="2" style="background:#4479BA; color: #FFFFFF;" align="center" |DLCO | ||
! rowspan="2" |Flow-Volume loop | |||
|- | |- | ||
! style="background:#4479BA; color: #FFFFFF;" align="center" |CXR | ! style="background:#4479BA; color: #FFFFFF;" align="center" |CXR | ||
Line 116: | Line 117: | ||
|- | |- | ||
! style="padding: 5px 5px; background: #DCDCDC;" align="center" |Asthma | ! style="padding: 5px 5px; background: #DCDCDC;" align="center" |Asthma | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | + | | style="padding: 5px 5px; background: #F5F5F5;" align="center" | + (night-time) | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | + | | style="padding: 5px 5px; background: #F5F5F5;" align="center" | + | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |± | | style="padding: 5px 5px; background: #F5F5F5;" align="center" |± | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |± | | style="padding: 5px 5px; background: #F5F5F5;" align="center" |± | ||
Line 142: | Line 143: | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | | | style="padding: 5px 5px; background: #F5F5F5;" align="center" | | ||
*Normal/↑ | *Normal/↑ | ||
| | |||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | | | style="padding: 5px 5px; background: #F5F5F5;" align="center" | | ||
* Pulmonary hyperinflation | * Pulmonary hyperinflation | ||
Line 157: | Line 159: | ||
|- | |- | ||
! style="padding: 5px 5px; background: #DCDCDC;" align="center" |Chronic bronchitis | ! style="padding: 5px 5px; background: #DCDCDC;" align="center" |Chronic bronchitis | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | + | | style="padding: 5px 5px; background: #F5F5F5;" align="center" | + (greater than equal to 3 months/year for greater than equal to 2 years) | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | + | | style="padding: 5px 5px; background: #F5F5F5;" align="center" | + (intermittent) | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | ± | | style="padding: 5px 5px; background: #F5F5F5;" align="center" | ± | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | + | | style="padding: 5px 5px; background: #F5F5F5;" align="center" | + | ||
Line 172: | Line 174: | ||
*Rales | *Rales | ||
*↓Bronchial breath sounds.(present in consolidation) | *↓Bronchial breath sounds.(present in consolidation) | ||
*Hyperresonance | |||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" | | ||
*↑Procalcitonin | *↑Procalcitonin | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" | | ||
* | *↓[[PaO2]] | ||
*↑[[PaCO2]] | |||
*↓[[pH]] | |||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" | | ||
*↓FEV1 | *↓FEV1 | ||
Line 183: | Line 188: | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" | | ||
*Normal | *Normal | ||
| | |||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" | | ||
* Thickening of the bronchial walls in the lower lobes | * Thickening of the bronchial walls in the lower lobes | ||
Line 194: | Line 200: | ||
*Chest radiograph | *Chest radiograph | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" | | ||
*Secondary to | *Secondary to chronic smoking | ||
*Blue-bloaters | |||
|- | |- | ||
! style="padding: 5px 5px; background: #DCDCDC;" align="center" |Bronchiolitis | ! style="padding: 5px 5px; background: #DCDCDC;" align="center" |Bronchiolitis | ||
Line 218: | Line 225: | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" | | ||
*↓ | *↓ | ||
| | |||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" | | ||
*Bronchovascular markings | *Bronchovascular markings | ||
Line 230: | Line 238: | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" | | ||
Can be associated with: | Can be associated with: | ||
*Organ transplantation | *[[Organ transplantation]] ([[bronchiolitis obliterans]]) | ||
|- | |- | ||
! style="padding: 5px 5px; background: #DCDCDC;" align="center" |Emphysema | ! style="padding: 5px 5px; background: #DCDCDC;" align="center" |Emphysema | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" | + (mild cough) | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" | + (severe, constant) | ||
| style="padding: 5px 5px; background: #F5F5F5;" |– | | style="padding: 5px 5px; background: #F5F5F5;" |– | ||
| style="padding: 5px 5px; background: #F5F5F5;" |<nowiki>+</nowiki> | | style="padding: 5px 5px; background: #F5F5F5;" |<nowiki>+</nowiki> | ||
Line 245: | Line 253: | ||
* Expiratory wheeze | * Expiratory wheeze | ||
* Hyperinflation | * Hyperinflation | ||
* Hyperresonance | |||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" | | ||
*↓alpha-1 antitrypsin | *↓alpha-1 antitrypsin | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" | | ||
* | *↓[[PaO2]] | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" | | ||
*↓FEV1 | *↓FEV1 | ||
Line 255: | Line 263: | ||
*↑ | *↑ | ||
| style="padding: 5px 5px; background: #F5F5F5;" |– | | style="padding: 5px 5px; background: #F5F5F5;" |– | ||
| | |||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" | | ||
* Flattening of the diaphragm | * Flattening of the diaphragm | ||
Line 266: | Line 275: | ||
*Pulse oximetry | *Pulse oximetry | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" | | ||
* Physical | * Physical exam | ||
* Spirometery | * Spirometery | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" | | ||
* Barrel Chest | * [[Barrel chest|Barrel Chest]] | ||
* [[Hepatitis]] | |||
* [[Fibromuscular dysplasia]] | |||
* [[Pancreatitis]] | |||
* Pink puffers | |||
* Secondary to chronic smoking (centrilobular emphysema) | |||
* Secondary to [[Alpha 1-antitrypsin deficiency|alpha- 1 antitrypsin deficiency]] (panacinar emphysema) | |||
|- | |- | ||
! style="padding: 5px 5px; background: #DCDCDC;" align="center" |Bronchiectasis | ! style="padding: 5px 5px; background: #DCDCDC;" align="center" |Bronchiectasis | ||
Line 294: | Line 309: | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" | | ||
*↓ | *↓ | ||
| | |||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" | | ||
*Tram track opacities | *Tram track opacities | ||
Line 334: | Line 350: | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" | | ||
*Normal | *Normal | ||
| | |||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" | | ||
* Bat wing appearance | * Bat wing appearance | ||
Line 351: | Line 368: | ||
! style="padding: 5px 5px; background: #DCDCDC;" align="center" |Tuberculosis | ! style="padding: 5px 5px; background: #DCDCDC;" align="center" |Tuberculosis | ||
| style="padding: 5px 5px; background: #F5F5F5;" |<nowiki>+</nowiki> | | style="padding: 5px 5px; background: #F5F5F5;" |<nowiki>+</nowiki> | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" | + (chronic) | ||
| style="padding: 5px 5px; background: #F5F5F5;" |<nowiki>+</nowiki> | | style="padding: 5px 5px; background: #F5F5F5;" |<nowiki>+</nowiki> | ||
| style="padding: 5px 5px; background: #F5F5F5;" |<nowiki>+</nowiki> | | style="padding: 5px 5px; background: #F5F5F5;" |<nowiki>+</nowiki> | ||
Line 360: | Line 377: | ||
| style="padding: 5px 5px; background: #F5F5F5;" |– | | style="padding: 5px 5px; background: #F5F5F5;" |– | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" | | ||
* Diminished breath sounds | * Diminished [[breath sounds]] | ||
* | * [[Rhonchi]]/[[wheeze]] | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" | | ||
* ↑[[C-reactive protein]] | * ↑[[C-reactive protein]] | ||
* [[Normocytic anemia]] | * [[Normocytic anemia]] | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" | | ||
* [[Respiratory acidosis]] | |||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" | | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" | | ||
*↑ | *↑ | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" | | ||
| | |||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" | | ||
* Upper lobe infiltrate | * Upper lobe infiltrate | ||
Line 398: | Line 417: | ||
| style="padding: 5px 5px; background: #F5F5F5;" | + | | style="padding: 5px 5px; background: #F5F5F5;" | + | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" | | ||
*Wheeze | *[[Wheeze]] | ||
*Hyperinflation | *Hyperinflation | ||
*Absent or | *Absent or ↓[[breath sounds]] | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" | | ||
* | *↑[[Vascular endothelial growth factor]]-D | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" | | ||
*Respiratory acidosis in severe disease | *[[Respiratory acidosis]] in severe disease | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" | | ||
*↓FEV1:FVC | *↓FEV1:FVC | ||
Line 411: | Line 430: | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" | | ||
*↓DLCO | *↓DLCO | ||
| | |||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" | | ||
*Ground glass appearance | *Ground glass appearance | ||
*Interstetial pulmonary edema | *Interstetial [[pulmonary edema]] | ||
*Septal thickening | *Septal thickening | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" | | ||
*Pulmonary cyst | *[[Pulmonary cystic lymphangiectasis|Pulmonary cyst]] | ||
*Pnuemothorax | *[[Pneumothorax|Pnuemothorax]] | ||
*Pleural masses | *[[Pleural]] masses | ||
*Pleural thickening | *[[Pleural]] thickening | ||
* | *[[Mediastinal]] [[lymphadenopathy]] | ||
*Pleural effusion | *[[Pleural effusion]] | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" | | ||
*VQ | *VQ scan | ||
*PET | *[[PET scan]] | ||
*Advanced lymphatic imaging | *Advanced lymphatic imaging | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" | | ||
Line 448: | Line 468: | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" | | ||
*↑TLC | *↑TLC | ||
* | *↑[[Glucose]] | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" | | ||
* | *↑[[PaCO2]] | ||
* | *↓[[PaO2]] | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" | | ||
*↓FEV1:FVC | *↓FEV1:FVC | ||
Line 459: | Line 479: | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" | | ||
*↑DLCO | *↑DLCO | ||
| | |||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" | | ||
*Pulmonary hyperinflation | *Pulmonary hyperinflation | ||
Line 481: | Line 502: | ||
| style="padding: 5px 5px; background: #F5F5F5;" | - | | style="padding: 5px 5px; background: #F5F5F5;" | - | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" | | ||
*Crackles | *[[Crackles]] | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" | | ||
*Sweat | *[[Sweat chloride test|Sweat chloride tes]]<nowiki/>t: >60 mEq/L | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" | | ||
* | *↑[[PaCO2]] | ||
* | *↓[[PaO2]] | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" | | ||
*↓FEV1:FVC | *↓FEV1:FVC | ||
Line 493: | Line 514: | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" | | ||
*↓ In severe lung impairment<ref name="pmid12814143">{{cite journal |vauthors=Espiritu JD, Ruppel G, Shrestha Y, Kleinhenz ME |title=The diffusing capacity in adult cystic fibrosis |journal=Respir Med |volume=97 |issue=6 |pages=606–11 |date=June 2003 |pmid=12814143 |doi= |url=}}</ref> | *↓ In severe lung impairment<ref name="pmid12814143">{{cite journal |vauthors=Espiritu JD, Ruppel G, Shrestha Y, Kleinhenz ME |title=The diffusing capacity in adult cystic fibrosis |journal=Respir Med |volume=97 |issue=6 |pages=606–11 |date=June 2003 |pmid=12814143 |doi= |url=}}</ref> | ||
| | |||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" | | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" | |
Revision as of 04:08, 19 March 2018
Obstructive lung disease Microchapters |
Differentiating Obstructive Lung Disease from other Diseases |
---|
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Usama Talib, BSc, MD [2], Feham Tariq, MD [3], Dildar Hussain, MBBS [4]
Overview
An obstructive lung disease is a group of diseases characterized by various deformities that result in the collapse of airways. Patients suffering from obstructive lung disease usually present with shortness of breath due to damage to the airways within the lungs. This results in an inability to exhale air completely and an abnormally high amount of air may still present in the lungs after the end of full expiration. One of the main etiology of the obstructive lung disease is long-term exposure to substances that irritate and damage the lung epithelium and lung parenchyma.This includes cigarette smoke, air pollution, chemical fumes, or dust etc. Patients are usually asymptotic during the initial phase of the disease, symptoms usually become more evident as the disease process gets worse. The symptoms usually include a productive cough, difficulty in breathing, wheezing, and tightness in the chest.These diseases include asthma, COPD, bronchiolitis, bronchiectasis, heart failure, tuberculosis, cystic fibrosis, and lymphangioleiomyomatosis. Obstructive lung diseases present with an obstructive pattern that is an increase in total lung capacity (TLC), increase in respiratory volume (RV), a decrease in forced vital capacity (FVC), a decreased forced expiratory volume (FEV1), and a decreased FEV1/FVC, on pulmonary function tests.
Classification
Various diseases that present with an obstructive pattern on pulmonary function tests include:
- Asthma
- COPD
- Bronchiolitis
- Bronchiectasis
- Heart failure
- Tuberculosis
- Lymphangioleiomyomatosis
- Cystic fibrosis
Spirometry Findings in Various Lung Conditions
Spirometry can help distinguish obstructive lung disease from restrictive lung disease. On spirometry the findings include:[1][2]
|
Approach to Lung Disorders
Spirometry | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Low FEV1/FVC ratio | Normal to high FEV1/FVC ratio | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Obstructive Lung Disease | Restrictive Lung Disease | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Bronchodilator therapy | DLCO | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Increased FEV1 | No change in FEV1 | Normal DLCO | Decreased DLCO | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Asthma | COPD | Chest wall disorders | Interstitial Lung Disease | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Differentiating Obstructive Lung Disease from other Diseases
Various diseases presenting with obstructive pattern on pulmonary function tests can be differentiated from each other as follows:
Diseases | Clinical manifestations | Diagnosis | |||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Symptoms | Signs | Lab findings | PFT | Imaging | Gold standard | Other features | |||||||||||||||
Cough | Dyspnea | Hemoptysis | Fever | Weight loss | Cyanosis | Clubbing | JVD | Peripheral edema | Auscultation | ABGs | FEV1/FVC | TLC | DLCO | Flow-Volume loop | |||||||
CXR | CT scan | Other tests | |||||||||||||||||||
Asthma | + (night-time) | + | ± | ± | − | − | − | − | − |
|
|
|
FEV1:FVC =<0.7 |
|
|
|
|
|
|
Associated with:
| |
Chronic bronchitis | + (greater than equal to 3 months/year for greater than equal to 2 years) | + (intermittent) | ± | + | − | − | − | − | − |
|
|
|
|
|
|
|
Microbiological testing is done in cases of:
|
|
| ||
Bronchiolitis | + | + | − | + | − | − | − | − | – |
|
|
|
|
|
|
|
|
|
Can be associated with: | ||
Emphysema | + (mild cough) | + (severe, constant) | – | + | + | + | + | – | – |
|
|
|
|
|
– |
|
|
|
|
| |
Bronchiectasis | + | + | + | + | – | + | + | – | – |
|
|
|
|
|
|
|
|
| |||
Heart failure | + | + | – | – | – | + | – | + | + |
|
|
|
|
|
|
|
|||||
Tuberculosis | + | + (chronic) | + | + | + | – | – | – | – |
|
|
|
|
||||||||
Lymphangioleiomyomatosis | + | + | +(<5%) | - | - | - | +(rare) | - | + |
|
|
|
|
|
|
|
|
|
| ||
Status Asthmaticus | + | + | - | ± | - | - | - | + | - |
|
|
|
|
|
|
- |
|
|
| ||
Cystic fibrosis | + | + | + | + | - | + | + | - | - |
|
|
|
|
References
- ↑ Pellegrino R, Viegi G, Brusasco V, Crapo RO, Burgos F, Casaburi R, Coates A, van der Grinten CP, Gustafsson P, Hankinson J, Jensen R, Johnson DC, MacIntyre N, McKay R, Miller MR, Navajas D, Pedersen OF, Wanger J (November 2005). "Interpretative strategies for lung function tests". Eur. Respir. J. 26 (5): 948–68. doi:10.1183/09031936.05.00035205. PMID 16264058.
- ↑ Mehrparvar AH, Sakhvidi MJ, Mostaghaci M, Davari MH, Hashemi SH, Zare Z (2014). "Spirometry values for detecting a restrictive pattern in occupational health settings". Tanaffos. 13 (2): 27–34. PMC 4260070. PMID 25506373.
- ↑ Gaeta M, Minutoli F, Girbino G, Murabito A, Benedetto C, Contiguglia R, Ruggeri P, Privitera S (2013). "Expiratory CT scan in patients with normal inspiratory CT scan: a finding of obliterative bronchiolitis and other causes of bronchiolar obstruction". Multidiscip Respir Med. 8 (1): 44. doi:10.1186/2049-6958-8-44. PMC 3710098. PMID 23835554.
- ↑ Park JE, Kim Y, Lee SW, Shim SS, Lee JK, Lee JH (2016). "The usefulness of low-dose CT scan in elderly patients with suspected acute lower respiratory infection in the emergency room". Br J Radiol. 89 (1060): 20150654. doi:10.1259/bjr.20150654. PMC 4846199. PMID 26861744.
- ↑ Espiritu JD, Ruppel G, Shrestha Y, Kleinhenz ME (June 2003). "The diffusing capacity in adult cystic fibrosis". Respir Med. 97 (6): 606–11. PMID 12814143.